digene HPV Genotyping PS Test

For HPV genotyping of HC2 positive samples

S_1084_5_GEN_disclaimer

✓ 24/7 automatic processing of online orders

✓ Knowledgeable and professional Product & Technical Support

✓ Fast and reliable (re)-ordering

digene HPV Genotyping PS Test

Cat. No. / ID:   613615

For 96 reactions, includes: primers, reagents, buffers and accessories using Hybrid Capture 2 (HC2) technology
This product contains substances regulated under REACH (EC 1907/2006 Annex XIV). The use of this product in the EU is permitted subject to an exemption (Article 56(3)). Please refer to the REACH notification and the SDS of this product, both of which can be found in the “Resources” section of this page, for more information.
The digene HPV Genotyping PS Test is intended for in vitro diagnostic use.

✓ 24/7 automatic processing of online orders

✓ Knowledgeable and professional Product & Technical Support

✓ Fast and reliable (re)-ordering

Features

  • Individual detection of HPV types 16, 18, and 45
  • Highly specific RNA probes for each genotype
  • Clinically proven Hybrid Capture 2 technology
  • Qualitative test results
  • Full compliance with EU IVD Directive 98/79/EC

Product Details

The digene HPV Genotyping PS Test is a reflex test intended of the qualitative detection of high-risk HPV types 16, 18, and 45 following a positive digene HC2 High-Risk HPV DNA Test result. The identification of high-risk HPV types 16, 18, and 45 provides additional information to aid in the clinical management of women in cervical cancer screening programs.

Performance

The digene HPV Genotyping PS Test is CE-IVD marked for in vitro diagnostic use.

The digene HPV Genotyping PS Test showed high test result agreement in identifying HPV types 16, 18, and 45 in comparison with a validated quantitative PCR HPV Genotyping test. The comparison included 287 PreservCyt and 290 STM archived cervical specimens obtained from a routine screening population. The digene HC2 High-Risk HPV DNA Test result was determined for each specimen prior to inclusion in the study. The results of the digene HC2 High-Risk HPV DNA Test were 238 positive and 52 negative STM specimens and 237 positive and 50 negative PreservCyt specimens. Each specimen was tested for HPV 16, 18, and 45 separately, with both the digene HPV Genotyping PS Test and the qPCR. The total agreement between the digene HPV Genotyping PS Test and the qPCR method was 99.4% (see table).

Agreement between the digene HPV Genotyping PS Test and the qPCR test method
  digene HPV Genotyping PS Test
  +
qPCR + 110 4
qPCR – 7 1610

The test agreement of the digene HPV Genotyping PS Test to the qPCR test was determined based on the HPV genotype (see table).

Test result agreement of the digene HPV Genotyping PS Test and the qPCR test for HPV genotype
Genotype Agreement% (n/N) 95% CI
HPV 16 99.1% (572/577) 98.0–99.6
HPV 18 99.7% (575/577) 98.7–99.9
HPV 45 99.3% (573/577) 98.2–99.7

Using the digene HPV Genotyping PS Test offers analytical specificity with no cross-reactivity between the 3 HPV probe mixes and the following HPV plasmid DNA:

  • High-risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82
  • Low-risk HPV types 1, 2, 3, 4, 5, 6, 8, 11, 13, 30, 34, 40, 42, 43, 44, 67, 69, 70, and 71

Principle

The digene HPV Genotyping PS Test is an in vitro nucleic acid hybridization assay with signal amplification using microplate chemiluminescence for the qualitative detection of the 3 high-risk types of HPV DNA in cervical specimens. The assay is intended as a reflex test to a positive digene HC2 High-Risk HPV DNA Test result, to determine the presence or absence of 16, 18, or 45 genotypes.

 HPV types 16, 18, and 45 are the most commonly found high-risk HPV types associated with squamous cell carcinoma and adenocarcinoma. A recent study of HPV genotypes shows that invasive cervical cancers which are related to HPV types 16, 18, and 45 are diagnosed on average 4 years earlier than cervical cancers associated with other high-risk HPV types. (de Sanjose, S. et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet 11, 1048.)

Samples collected with the digene Cervical Sampler may be used with the digene HPV Genotyping PS Test.

Procedure

The digene HPV Genotyping PS Test utilizes the familiar format of Hybrid Capture 2 (HC2) chemistry, using type-specific oligoribonucleotides, antibody capture, and qualitative chemiluminescent signal detection.

The digene HPV Genotyping PS Test, performed in triplicate for each cervical specimen, genotypes for 3 high-risk types (16, 18, and 45) of HPV DNA in cervical specimens. After denaturation, specimens are hybridized with specific HPV RNA probes which target the full HPV genome. The resultant RNA:DNA hybrids are captured onto the surface of a microplate well coated with antibodies specific for RNA:DNA hybrids. In the digene HPV Genotyping PS Test, the formation of hybrids and their subsequent capture onto the surface of the microplate occur simultaneously during a single step. Immobilized hybrids then react with specific alkaline phosphotase-conjugated and are detected with a chemiluminescent substrate using the DML 2000 or DML 3000 instrument.

Applications

The digene HPV Genotyping PS Test is a reflex test intended for the qualitative detection of high-risk HPV types 16, 18, and 45 following a positive digene HC2 High-Risk HPV DNA Test result. The digene HPV Genotyping PS Test may be used for testing women in cervical cancer screening programs.

Supporting data and figures

Resources

Safety Data Sheets (2)
Download Safety Data Sheets for QIAGEN product components.
Kit Handbooks (1)
For the qualitative detection of human papillomavirus (HPV) types 16, 18, and 45. For use with the digene HC2 High-Risk HPV DNA Test.
Certificates of Analysis (1)